Lidorestat

Drug Profile

Lidorestat

Alternative Names: EML 676; IDD 676; lindolrestat; lindorestat

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute for Diabetes Discovery LLC
  • Class Antihyperglycaemics; Indoleacetic acids; Small molecules; Thiazoles
  • Mechanism of Action Aldehyde reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetic neuropathies

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Diabetic-neuropathies in North America (PO)
  • 28 Sep 2005 A preclinical study has been added to the pharmacokinetics and Diabetes pharmacodynamics sections
  • 31 Aug 2005 The Institute for Diabetes Discovery and Alinea Pharmaceuticals have entered into an agreement to co-develop lidorestat for diabetic complications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top